CeriBell, Inc. (CBLL) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for CeriBell, Inc. (CBLL) due to higher revenues, with a focus on how actual results will compare to estimates impacting stock price [1][2]. Earnings Expectations - CeriBell, Inc. is expected to report a quarterly loss of $0.43 per share, reflecting a year-over-year change of +76.8% [3]. - Revenues are projected to be $21.79 million, which is an increase of 26.8% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 2.33% higher in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for CeriBell, Inc. is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.10% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a likely earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - CeriBell, Inc. currently holds a Zacks Rank of 3, indicating a potential to beat the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, CeriBell, Inc. was expected to post a loss of $0.40 per share but delivered a loss of -$0.38, resulting in a surprise of +5.00% [13]. - Over the past four quarters, the company has surpassed consensus EPS estimates two times [14]. Industry Comparison - Owens & Minor (OMI), another player in the Zacks Medical - Products industry, is expected to report an EPS of $0.23, reflecting a year-over-year change of -45.2% [18]. - Revenues for Owens & Minor are expected to be $700.91 million, down 74.2% from the previous year [18].